<DOC>
	<DOCNO>NCT00637377</DOCNO>
	<brief_summary>This study phase III , double-masked , randomize , study efficacy safety VEGF Trap-Eye patient neovascular age-related macular degeneration . Approximately 1200 patient randomize Europe , Asia , Japan , Australia South America .</brief_summary>
	<brief_title>Vascular Endothelial Growth Factor ( VEGF ) Trap-Eye : Investigation Efficacy Safety Wet Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>Data trial ( `` VIEW 2 '' ) pool data sister trial ( `` VIEW 1 '' , NCT00509795 ) , integrate analysis combine data perform .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent . Men woman &gt; /=50 year age . Active primary recurrent subfoveal CNV lesion secondary AMD , include juxtafoveal lesion affect fovea evidence Fluorescein angiography ( FA ) study eye . ETDRS BestCorrected Visual Acuity letter score 73 25 ( = Acuity 20/40 20/320 ) study eye 4 meter . Willing , commit , able return ALL clinic visit complete studyrelated procedure . Able read , ( , unable read due visual impairment , read verbatim person administer informed consent family member ) understand willing sign inform consent form . Any prior ocular ( study eye ) systemic treatment surgery neovascular AMD , except dietary supplement vitamin . Any prior concomitant therapy another investigational agent treat neovascular AMD study eye . Any prior treatment antiVEGF agent study eye . Total lesion size &gt; 12 disc area ( 30.5 mm , include blood , scar neovascularization ) assess FA study eye . Subretinal hemorrhage either 50 % total lesion area , blood fovea 1 disc area size study eye ( blood fovea , fovea must surround 270 degree visible CNV ) . Scar fibrosis make &gt; 50 % total lesion study eye . Scar , fibrosis , atrophy involve center fovea study eye . Presence retinal pigment epithelial tear rip involve macula study eye . History vitreous hemorrhage within 4 week prior Visit 1 study eye . Presence cause CNV study eye . Prior vitrectomy study eye . History retinal detachment treatment surgery retinal detachment study eye . Any history macular hole stage 2 study eye . Any intraocular periocular surgery within 3 month Day 1 study eye , except lid surgery , may take place within 1 month Day 1 , long unlikely interfere injection . History clinical evidence diabetic retinopathy , diabetic macular edema retinal vascular disease AMD either eye .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Eye disease</keyword>
	<keyword>Vision Impairment Blindness</keyword>
	<keyword>Eyes Vision</keyword>
	<keyword>Seniors</keyword>
	<keyword>Neovascular Age-Related Macular Degeneration ( AMD )</keyword>
	<keyword>Retinal Disease</keyword>
</DOC>